 |
Ulf Björklund
CEO, M.Sc. in Pharmacy, has over 25 years of experience from the drug development and pharmaceutical industry, the larger part of which he has held managerial positions. Prior to joining Aprea, he was CEO of OxyPharma, a Swedish drug Development Company focusing on autoimmune diseases. Prior to joining OxyPharma 2002 he was Head of Clinical Operations for the Nordic countries of Pharmacia. Before that he held several other positions with Pharmacia covering clinical research in many therapeutic areas. He is a member of the Educational Counsel for Clinical Trials, the Swedish Pharmaceutical Society.
 ulf.bjorklund @ aprea.com
|
 |
Nina Mohell
VP Discovery, Ph.D., has prior to her position at Aprea been working at various senior positions at AstraZeneca, Acadia and Biovitrum. She is Adjunct Professor at the Faculty of Medicine, Uppsala University.
nina.mohell @ aprea.com
|
 |
Kimmo Sinervo
CFO, Business Administration.
kimmo.sinervo @ aprea.com
|
 |
Jessica Alfredsson
Ph.D., Scientist, is responsible for various activities at the laboratory at Aprea.
jessica.alfredsson @ aprea.com
|
 |
Maria Uustalu
M.Sc., Laboratory Engineer, is mainly working with screening of compounds in various cancer models. Currently on maternity leave.
maria.uustalu @ aprea.com
|
 |
Åsa Fransson
Ph.D., Scientist, is mainly working with screening of compounds in various cancer models. Substitute for Maria Uustalu who is currently on maternity leave.
asa.fransson @ aprea.com
|
| |
|
|
